Медицинская литература. Новинки

 

 

 

 

 

 

Радиочастотная абляция при внутрипеченочном холангиоцеллюлярном раке (клиническое наблюдение)

Вы можете загрузить полный текст статьи в формате pdf

Внутрипеченочный холангиоцеллюлярный рак является первичной аденокарциномой внутрипеченочных желчных протоков и второй по распространенности опухолью печени. Резекция печени остается наиболее эффективным методом лечения. Однако возможности хирургического лечения могут быть ограничены нерезектабельностью опухоли и неоперабельностью больного в связи с сопутствующими заболеваниями. Известно, что радиочастотная абляция эффективна при лечении гепатоцеллюлярной карциномы и метастазов колоректального рака в печени, однако о ее эффективности при внутрипеченочном холангиоцеллюлярном раке сообщается лишь в нескольких клинических наблюдениях. Накопление опыта локальных методов деструкции при внутрипеченочном холангиоцеллюлярном раке, особенно у неоперабельных больных, представляет клиническую ценность. В клиническом наблюдении представлен результат эффективного лечения пациента с внутрипеченочным холангиоцеллюлярным раком на фоне цирроза печени с помощью радиочастотной абляции. Безрецидивная выживаемость составила 44 мес.

Ключевые слова:
печень, желчные протоки, холангиоцеллюлярный рак, радиочастотная абляция, хирургическое лечение, отдаленные результаты, liver, bile ducts, cholangiocarcinoma, radiofrequency ablation, surgical treatment, long-term results

Литература:
1.Buettner S., van Vugt J.L., Ijzermans J.N., Groot Koerkamp B. Intrahepatic cholangiocarcinoma: current perspectives. Onco Targets Ther. 2017; 10: 1131-1142. https://doi.org/10.2147/OTT.S93629
2.Park J., Kim M.H., Kim K.P., Park D.H., Moon S.H., Song T.J.,Eum J., Lee S.S., Seo D.W., Lee S.K. Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study. Gut Liver. 2009; 3 (4): 298-305. https://doi.org/10.5009/gnl.2009.3.4.298
3.Jarnagin W.R., Shoup M. Surgical management of cholangiocarcinoma. Sem in Liver Dis. 2004; 24 (2): 189-199. https://doi.org/10.1055/s-2004-828895
4.Ионкин Д.А., Вишневский В.А., Жаворонкова О.И., Шуракова А.Б., Чжао А.В. Радиочастотная абляция при метастазах колоректального рака в печень. Высоко технологическая медицина. 2014; 2: 17-37.
5.Butros S.R., Shenoy-Bhangle A., Mueller P.R., Arellano R.S. Radiofre-quency ablation of intrahepatic cholangiocarcinoma: feasability, local tumor control, and long-term outcome. Clin. Imaging. 2014; 38 (4): 490-494. https://doi.org/10.1016/j.clinimag.2014.01.013
6.Shindoh J. Ablative therapies for intrahepatic cholangiocarcinoma. HepatoBiliary Surg. Nutr. 2017; 6 (1): 2-6. https://doi.org/10.21037/hbsn.2016.09.07
7.Spolverato G., Kim Y., Alexandrescu S., Marques H.P., Lamelas J., Aldrighetti L., Clark Gamblin T., Maithel S.K., Pulitano C., Bauer T.W., Shen F., Poultsides G.A., Tran T.B., Wallis Marsh J., Pawlik T.M. Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative-intent surgical resection. Ann. Surg. Oncol. 2016; 23 (1): 235-243. https://doi.org/10.1245/s10434-015-4642-9
8.Tiong L., Maddern G.J. Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma. Br. J. Surg. 2011; 98 (9): 1210-1224. https://doi.org/10.1002/bjs.7669
9.Simo K.A., Halpin L.E., McBrier N.M., Marques H.P., Lamelas J., Aldrighetti L., Clark Gamblin T., Maithel S.K., Pulitano C., Bauer T.W., Shen F., Poultsides G.A., Tran T.B., Wallis Marsh J., Pawlik T.M. Multimodality treatment of intrahepatic cholangio carcinoma: A review. J. Surg. Oncol. 2016; 113 (1): 62-83. https://doi.org/10.1002/jso.24093.
10.Chiou Y.Y., Hwang J.I., Chou Y.H., Wang H-K., Chiang J.-H., Chang Ch.-Y. Percutaneous ultrasound-guided radiofrequency ablation of intrahepatic cholangiocarcinoma. Kaohsiung J. Med. Sci. 2005; 21 (7): 304-309. https://doi.org/10.1259/bjr/24563774
11.Carrafiello G., Lagana` D., Cotta E., Mangini M., Fontana F., Bandiera F., Fugazzola C. Radiofrequency ablation of intrahepatic cholangiocarcinoma: preliminary experience. Cardiovasc. Intervent. Radiol. 2010; 33 (4): 835-839. https://doi.org/10.1007/s00270-010-9849-3.
12.Kamphues C., Seehofer D., Eisele R.M., Pratschke J., Neumann U.P., Neuhaus P. Recurrent intrahepatic cholangiocarcinoma: single-center experience using repeated hepatectomy and radiofrequency ablation. J. Hepatobiliary Pancreat. Sci. 2010; 17 (4): 509-515. https://doi.org/10.1007/s00534-009-0256-6
13.Kim J.H., Won H.J., Shin Y.M., Kim K.A., Kim P.N. Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma. Am. J. Roentgenol. 2011; 196 (2): 205-209. https://doi.org/10.2214/AJR.10.4937.
14.Giorgio A., Calisti G., DE Stefano G., Farella N., Di Sarno A., Amendola F., Scognamiglio U., Giorgio V. Radiofrequency ablation for intrahepatic cholangiocarcinoma: retrospective analysis of a single centre experience. Anticancer Res. 2011; 31 (12): 4575-4580.
15.Kim J.H., Won H.J., Shin Y.M., Kim P.N., Lee S.G., Hwang S. Radiofrequency ablation for recurrent intrahepatic cholangiocarcinoma after curative resection. Eur. J. Radiol. 2011; 80 (3): e221-225. https://doi.org/10.1016/j.ejrad.2010.09.019
16.Yu M.A., Liang P., Yu X.L., Cheng Z.G., Han Z.Y., Liu F.Y., Yu J. Sonography-guided percutaneous microwave ablation of intrahepatic primary cholangiocarcinoma. Eur. J. Radiol. 2011; 80 (2): 548-552. https://doi.org/10.1259/bjr/24563774
17.Xu H.X., Wang Y., Lu M.D., Liu L.N. Percutaneous ultrasound-guided thermal ablation for intrahepatic cholangiocarcinoma. Br. J. Radiol. 2012; 85 (1016): 1078-1084. https://doi.org/10.1259/bjr/245637748.
18.Haidu M., Dobrozemsky G., Schullian P., Widmann G., Klaus A., Weiss H., Margreiter R., Bale R. Stereotactic radiofrequency ablation of unresectable intrahepatic cholangiocarcinomas: a retrospective study. Cardiovasc. Intervent. Radiol. 2012; 35 (3): 1074-1082. https://doi.org/10.1007/s00270-011-0288-6
19.Zhang S.J., Hu P., Wang N., Shen Q., Sun A.X., Kuang M., Qian G.J. Thermal ablation versus repeated hepatic resection for recurrent intrahepatic cholangiocarcinoma. Ann. Surg. Oncol. 2013; 20 (11): 3596-3602. https://doi.org/10.1245/s10434-013-3035-1
20.Vogl T.J., Schwarz W., Eichler K., Hochmuth K., Hammerstingl R., Jacob U., Scheller A., Zangos S., Heller M. Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy. J. Cancer Res. Clin. Oncol. 2006; 132 (11): 745-755. https://doi.org/10.1007/s00432-006-0138-0
21.Burger I., Hong K., Schulick R., Georgiades C., Thuluvath P., Choti M., Kamel I., Geschwind J.F. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J. Vasc. Interv. Radiol. 2005; 16 (3): 353-361. https://doi.org/10.1097/01.RVI.0000143768.60751.78
22.Kiefer M.V., Albert M., McNally M., Robertson M., Sun W., Fraker D., Olthoff K., Christians K., Pappas S., Rilling W., Soulen M.C. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. Cancer. 2011; 117 (7): 1498-1505. https://doi.org/10.1002/cncr.25625
23.Amini N., Ejaz A., Spolverato G., Kim Y., Herman J.M., Pawlik T.M. Temporal trends in liver-directed therapy of patients with intrahepatic cholangiocarcinoma in the United States: a population based analysis. J. Surg. Oncol. 2014; 110 (2): 163-170. https://doi.org/10.2147/OTT.S93629
24.Han K., Ko H.K., Kim K.W., Won H.J., Shin Y.M., Kim P.N. Radiofrequency ablation in the treatment of unresectable intrahepatic cholangiocarcinoma: systematic review and metaanalysis. JVIR. 2015; 26 (7): 943-948. https://doi.org/10.2214/AJR.10.4937
25.Fu Y., Yang W., Wu W., Yan K., Xing B.C., Chen M.H. Radiofrequency ablation in the management of unresectable intrahepatic cholangiocarcinoma. J. Vasc. Interv. Radiol. 2012; 23 (5): 642-649. https://doi.org/10.1016/j.jvir.2012.01.081

Radiofrequency ablation of intrahepatic cholangiocarcinoma (clinical observation)

Intrahepatic cholangiocarcinoma is the primary adenocarcinoma of the intrahepatic bile ducts and the second most common liver tumor. Liver resection remains the most effective treatment. However, the possibilities of surgical treatment may be limited by the unresectability of the tumor and the inoperability of the patient due to concomitant diseases. It is known that radiofrequency ablation is effective in the treatment of hepatocellular carcinoma and metastases of colorectal cancer in the liver, however, only a few clinical observations have been reported regarding its effectiveness in intrahepatic cholangiocarcinoma. The accumulation of experience regarding the effectiveness of local destruction methods in intrahepatic cholangiocarcinoma especially in inoperable patients is of clinical value. The accumulation of experience with local destruction methods in intrahepatic cholangiocarcinoma, especially in inoperable patients, is of clinical value. This clinical observation presents the result of effective treatment of a patient with intrahepatic cholangiocarcinoma with cirrhosis using radiofrequency ablation. Relapse-free survival in this case was 44 months.

Keywords:
печень, желчные протоки, холангиоцеллюлярный рак, радиочастотная абляция, хирургическое лечение, отдаленные результаты, liver, bile ducts, cholangiocarcinoma, radiofrequency ablation, surgical treatment, long-term results